Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes.

Avliyakulov NK, Sobolevsky T, Ahrens E

Drug testing and analysis13 Feb 2026

PMID41688415DOI10.1002/dta.70035PepBankPUB-41688415

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, SLU-PP-332 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking SLU-PP-332.

01LabNot a test of SLU-PP-332 aloneIn vitro (cell-free)Pharmacokinetics
In human liver S9 fractions, five monohydroxylated SLU‑PP‑332 metabolites were identified.
In plain wordsIn lab tests, researchers identified five monohydroxylated SLU‑PP‑332 metabolites.
Peptide
SLU-PP-332
Outcome
Not applicableMonohydroxylated metabolites
Study
humann: not reported in source
Pooled human liver S9 fractions
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Five monohydroxylated (M1-M5), three dihydroxylated (M6-M8), and four reduced dihydroxylated metabolites (M9-M12) were identified.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of the study was identification of Phase I and II metabolites generated in vitro using pooled human liver S9 fractions.
Summary · context
Metabolites were analyzed using liquid chromatography-high-resolution mass spectrometry (LC-MS/HRMS).
In this study, SLU-PP-332 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SLU-PP-332.
Report a problemFND-4168841501
02LabNot a test of SLU-PP-332 aloneIn vitro (cell-free)Pharmacokinetics
In human liver S9 fractions, three dihydroxylated SLU‑PP‑332 metabolites were identified.
In plain wordsIn lab tests, researchers identified three dihydroxylated SLU‑PP‑332 metabolites.
Peptide
SLU-PP-332
Outcome
Not applicableDihydroxylated metabolites
Study
humann: not reported in source
Pooled human liver S9 fractions
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Five monohydroxylated (M1-M5), three dihydroxylated (M6-M8), and four reduced dihydroxylated metabolites (M9-M12) were identified.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of the study was identification of Phase I and II metabolites generated in vitro using pooled human liver S9 fractions.
Summary · context
Metabolites were analyzed using liquid chromatography-high-resolution mass spectrometry (LC-MS/HRMS).
In this study, SLU-PP-332 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SLU-PP-332.
Report a problemFND-4168841502
03LabNot a test of SLU-PP-332 aloneIn vitro (cell-free)Pharmacokinetics
In human liver S9 fractions, four reduced dihydroxylated SLU‑PP‑332 metabolites were identified.
In plain wordsIn lab tests, researchers identified four reduced dihydroxylated SLU‑PP‑332 metabolites.
Peptide
SLU-PP-332
Outcome
Not applicableReduced dihydroxylated metabolites
Study
humann: not reported in source
Pooled human liver S9 fractions
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Five monohydroxylated (M1-M5), three dihydroxylated (M6-M8), and four reduced dihydroxylated metabolites (M9-M12) were identified.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of the study was identification of Phase I and II metabolites generated in vitro using pooled human liver S9 fractions.
Summary · context
Metabolites were analyzed using liquid chromatography-high-resolution mass spectrometry (LC-MS/HRMS).
In this study, SLU-PP-332 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SLU-PP-332.
Report a problemFND-4168841503
04LabNot a test of SLU-PP-332 aloneIn vitro (cell-free)Pharmacokinetics
In human liver S9 fractions, SLU‑PP‑332 metabolite M13 showed direct glucuronidation of the parent compound.
In plain wordsIn lab tests, SLU‑PP‑332 metabolite M13 showed direct glucuronidation.
Peptide
SLU-PP-332
Outcome
Not applicableDirect glucuronidation
Study
humann: not reported in source
Pooled human liver S9 fractions
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Metabolites M13 and M19 showed direct glucuronidation and sulfation of the parent compound, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of the study was identification of Phase I and II metabolites generated in vitro using pooled human liver S9 fractions.
Summary · context
Metabolites were analyzed using liquid chromatography-high-resolution mass spectrometry (LC-MS/HRMS).
In this study, SLU-PP-332 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SLU-PP-332.
Report a problemFND-4168841504
05LabNot a test of SLU-PP-332 aloneIn vitro (cell-free)Pharmacokinetics
In human liver S9 fractions, SLU‑PP‑332 metabolite M19 showed direct sulfation of the parent compound.
In plain wordsIn lab tests, SLU‑PP‑332 metabolite M19 showed direct sulfation.
Peptide
SLU-PP-332
Outcome
Not applicableDirect sulfation
Study
humann: not reported in source
Pooled human liver S9 fractions
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Metabolites M13 and M19 showed direct glucuronidation and sulfation of the parent compound, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of the study was identification of Phase I and II metabolites generated in vitro using pooled human liver S9 fractions.
Summary · context
Metabolites were analyzed using liquid chromatography-high-resolution mass spectrometry (LC-MS/HRMS).
In this study, SLU-PP-332 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SLU-PP-332.
Report a problemFND-4168841505
06LabNot a test of SLU-PP-332 aloneIn vitro (cell-free)Pharmacokinetics
In human liver S9 fractions, SLU‑PP‑332 metabolites M14-M18 showed glucuronidation with hydroxylation of the naphthalene ring.
In plain wordsIn lab tests, SLU‑PP‑332 metabolites M14-M18 showed glucuronidation with naphthalene ring hydroxylation.
Peptide
SLU-PP-332
Outcome
Not applicableGlucuronidation with hydroxylation
Study
humann: not reported in source
Pooled human liver S9 fractions
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Metabolites M14-M18 and M20-M22 showed glucuronidation and sulfation with hydroxylation of the naphthalene or phenolic rings, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of the study was identification of Phase I and II metabolites generated in vitro using pooled human liver S9 fractions.
Summary · context
Metabolites were analyzed using liquid chromatography-high-resolution mass spectrometry (LC-MS/HRMS).
In this study, SLU-PP-332 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SLU-PP-332.
Report a problemFND-4168841506
07LabNot a test of SLU-PP-332 aloneIn vitro (cell-free)Pharmacokinetics
In human liver S9 fractions, SLU‑PP‑332 metabolites M20-M22 showed sulfation with hydroxylation of the phenolic ring.
In plain wordsIn lab tests, SLU‑PP‑332 metabolites M20-M22 showed sulfation with phenolic ring hydroxylation.
Peptide
SLU-PP-332
Outcome
Not applicableSulfation with hydroxylation
Study
humann: not reported in source
Pooled human liver S9 fractions
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Metabolites M14-M18 and M20-M22 showed glucuronidation and sulfation with hydroxylation of the naphthalene or phenolic rings, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of the study was identification of Phase I and II metabolites generated in vitro using pooled human liver S9 fractions.
Summary · context
Metabolites were analyzed using liquid chromatography-high-resolution mass spectrometry (LC-MS/HRMS).
In this study, SLU-PP-332 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SLU-PP-332.
Report a problemFND-4168841507
08LabNot a test of SLU-PP-332 aloneIn vitro (cell-free)Pharmacokinetics
In human liver S9 fractions, M1, M7, M9, M10, M13, M14, M19, and M20 were the most abundant SLU‑PP‑332 metabolites.
In plain wordsIn lab tests, M1, M7, M9, M10, M13, M14, M19, and M20 were the most abundant SLU‑PP‑332 metabolites.
Peptide
SLU-PP-332
Outcome
Not applicableMost abundant metabolites
Study
humann: not reported in source
Pooled human liver S9 fractions
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
M1, M7, M9, M10, M13, M14, M19, and M20 were the most abundant of the 22 metabolites and potentially useful for doping-control purposes.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of the study was identification of Phase I and II metabolites generated in vitro using pooled human liver S9 fractions.
Summary · context
Metabolites were analyzed using liquid chromatography-high-resolution mass spectrometry (LC-MS/HRMS).
In this study, SLU-PP-332 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SLU-PP-332.
Report a problemFND-4168841508
09LabNot a test of SLU-PP-332 aloneIn vitro (cell-free)Pharmacokinetics
In pooled human liver S9 fractions, researchers identified 22 SLU‑PP‑332 metabolites.
In plain wordsIn lab tests with human liver preparations, researchers identified 22 SLU‑PP‑332 metabolites.
Peptide
SLU-PP-332
Outcome
Not applicableTotal metabolite count
Study
humann: not reported in source
Pooled human liver S9 fractions
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
M1, M7, M9, M10, M13, M14, M19, and M20 were the most abundant of the 22 metabolites and potentially useful for doping-control purposes.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the study was identification of Phase I and II metabolites generated in vitro using pooled human liver S9 fractions.
In this study, SLU-PP-332 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking SLU-PP-332.
Report a problemFND-4168841509

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.